All In Biotech

Drug Trial Radar · NCT02340169

Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression and Pharmacokinetics Following Maximal Use Treatment With Topicort® (Desoximetasone) Topical Spray, 0.25% in Pediatric Patients With Plaque Psoriasis.

Last checked: Nov 20, 2026Latest source record: Mar 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

129

Actual

Start

Jan 23, 2015

Primary completion

Nov 22, 2019

Study completion Nov 22, 2021

Sponsor

Sponsor type
Industry
First posted
Jan 16, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the potential of Topicort® (desoximetasone) Topical Spray, 0.25% to suppress hypothalmic pituitary adrenal axis function. The secondary objectives are to evaluate the efficacy parameters, pharmacokinetics and adverse event profile.

Conditions

  • Plaque Psoriasis

Interventions

  • Topicort® (desoximetasone) Topical Spray, 0.25%Drug

    Topicort® (desoximetasone) Topical Spray, 0.25% applied to affected areas twice a day for 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Number of Participants With Hypothalmic Pituitary Adrenal Axis Function Suppression as Measured by Cortisol Response TestTime frame: 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Taro Pharmaceuticals USA Inc.

    Hawthorne, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.